Related Experiment Video
Updated: Apr 12, 2026

Routine Screening Method for Microparticles in Platelet Transfusions
Published on: January 31, 2018
Platelet miRNAs and cardiovascular diseases
Eduardo Fuentes1, Iván Palomo1, Marcelo Alarcón1
1Department of Clinical Biochemistry and Immunohaematology, Faculty of Health Sciences, Interdisciplinary Excellence Research Program on Healthy Aging (PIEI-ES), Universidad de Talca, Talca, Chile; Centro de Estudios en Alimentos Procesados (CEAP), CONICYT-Regional, Gore Maule R09I2001, Chile.
Platelet microRNAs (miRNAs) are key in atherosclerosis complications. These platelet-secreted miRNAs may serve as novel biomarkers for cardiovascular disease risk assessment.
Area of Science:
- Cardiovascular Biology
- Molecular Biology
- Biomarker Discovery
Background:
- Activated platelets are crucial in acute atherosclerotic complications, leading to ischemic events.
- MicroRNAs (miRNAs), small non-coding RNAs, significantly influence inflammatory and cardiovascular diseases.
- Platelets contain miRNAs that perform vital regulatory functions.
Purpose of the Study:
- To systematically investigate genes regulated by specific platelet miRNAs (miRNA-223, miRNA-126, miRNA-21, miRNA-24, miRNA-197).
- To explore the association between these platelet-derived miRNAs and cardiovascular disease risks.
- To identify potential novel biomarkers for cardiovascular diseases.
Main Methods:
- Systematic examination of gene regulation by selected platelet miRNAs.
- Analysis of the correlation between platelet miRNA profiles and cardiovascular disease risk factors.
Main Results:
- Identified specific genes regulated by platelet miRNAs (miRNA-223, miRNA-126, miRNA-21, miRNA-24, miRNA-197).
- Established associations between these miRNAs and cardiovascular disease risks.
- Demonstrated the presence and regulatory roles of miRNAs within platelets.
Conclusions:
- Platelet miRNAs are integral to cardiovascular disease pathogenesis.
- Platelet-secreted miRNAs show promise as novel biomarkers for cardiovascular diseases.
- Targeting platelet miRNAs could offer new therapeutic strategies for atherosclerosis.
Related Concept Videos
Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

